2. Academic Validation
  3. Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus

Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus

  • Virol Sin. 2022 Feb;37(1):145-148. doi: 10.1016/j.virs.2022.01.014.
Jingjing Yang 1,  Yunzheng Yan 2,  Qingsong Dai 2,  Jiye Yin 2,  Lei Zhao 2,  Yuexiang Li 2,  Wei Li 2,  Wu Zhong 2,  Ruiyuan Cao 3,  Song Li 4
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • 2 National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • 3 National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].
  • 4 School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].
PMID: 35234618 DOI: 10.1016/j.virs.2022.01.014
Abstract

  1. •

    Tilorone dihydrochloride possesses robust anti-SFTSV activity in vitro and in vivo.

  2. •

    Intraperitoneal administration of tilorone leads to protection against intracranial lethal challenge of SFTSV.

  3. •

    The anti-SFTSV mechanism of tilorone is through stimulation of host innate immunity.

  4. •

    Pre-treatment with tilorone can prevent mice from lethal SFTSV challenge.

Figures
Products